Lars Fruergaard Jørgensen, Novo Nordisk CEO (Christopher Goodney/Bloomberg via Getty Images)
Novo Nordisk drops two programs as it plots Wegovy comeback
Two Novo Nordisk programs in obesity and cardiovascular disease are on the chopping block, the company buried in its Q3 report, as CEO Lars Fruergaard Jørgensen plots a comeback in obesity.
The chief executive is shutting down a Phase I obesity program dubbed LA-GDF15 and a PCSK9 inhibitor that just completed a Phase II trial in patients with or at risk of developing atherosclerotic cardiovascular disease (ASCVD) due to “portfolio considerations,” he said in the Q3 report.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters